Karma Oncology is a specialized and unique oncology clinical development company established in 2012 by Dr Karen J Williams. Services include bespoke clinical development planning, clinical trial design and execution. Our business model permits us to be flexible in our approach allowing us to perform individual tasks on a clinical trial; or full-service provision for both biotech and pharmaceutical companies globally. The Karma Oncology team of experts, based across Europe and North America, has a wealth of experience in managing clinical trials in many types of solid tumors and hematological malignancies. Including the current “hot topic” novel immunotherapy treatments such as autologous cell therapy and CAR-T therapy. Karma Oncology partners with clients to ensure their oncology clinical trials meet sponsor timelines with good quality data. Positive, informed actions lead to positive results – that is the Karma approach.
There are two parts to the World Advanced Therapies & Regenerative Medicine Congress: a conference and an exhibition featuring solutions for pharma and biotech.
There is a registration fee to attend the conferences. To visit the exhibition is free.